HoSAGE: Sarcopenia in Older Patients before and after Treatment with Androgen Deprivation Therapy and Radiotherapy for Prostate Cancer.
Sarcopenia
androgen deprivation therapy
older patients
prostate cancer
radiotherapy
Journal
The journal of nutrition, health & aging
ISSN: 1760-4788
Titre abrégé: J Nutr Health Aging
Pays: France
ID NLM: 100893366
Informations de publication
Date de publication:
2020
2020
Historique:
entrez:
1
2
2020
pubmed:
1
2
2020
medline:
7
8
2020
Statut:
ppublish
Résumé
Sarcopenia is a muscle disease defined by a loss of muscle strength associated to a decrease in skeletal muscle mass. In addition to aging, many factors may contribute to sarcopenia as cancer and/or androgen deprivation therapy (ADT). The aims of this study are to describe the prevalence of sarcopenia in older prostate cancer patients before initiation of treatment with ADT and radiotherapy, and to evaluate the impact of ADT on the occurrence or aggravation of sarcopenia in this population. longitudinal study. Sarcopenia was prospectively evaluated in 31 consecutive patients aged 70 to 88 years, referred in one hospital unit of south eastern France, for a comprehensive geriatric assessment (CGA) before cancer treatment initiation. CGA, measures of muscle strength and physical performances were performed at baseline (T0) and at the end of cancer treatment (T1). Appendicular skeletal muscle mass was measured by Dual-energy X-ray absorptiometry (DXA) at the end of treatment. At T0, 8 patients (among 31) had a probable sarcopenia according to European consensus, and 18 had altered physical performance. At T1, 15 patients (among 19) had abnormal one leg balance test. Finally, only one patient had a sarcopenia confirmed by DXA. This preliminary study showed a high prevalence of muscle disorders before initiation of ADT in a population of elderly cancer prostate patients with intermediate frailty status, and an increased risk of falls at the end of ADT. This highlighted the importance of screening for sarcopenia before treatment initiation, to prevent the occurrence or aggravation of sarcopenia by possible adjustment of treatment, and implementation of appropriate exercise and nutrition interventions.
Sections du résumé
BACKGROUND
Sarcopenia is a muscle disease defined by a loss of muscle strength associated to a decrease in skeletal muscle mass. In addition to aging, many factors may contribute to sarcopenia as cancer and/or androgen deprivation therapy (ADT).
OBJECTIVES
The aims of this study are to describe the prevalence of sarcopenia in older prostate cancer patients before initiation of treatment with ADT and radiotherapy, and to evaluate the impact of ADT on the occurrence or aggravation of sarcopenia in this population.
DESIGN
longitudinal study.
PARTICIPANTS AND SETTING
Sarcopenia was prospectively evaluated in 31 consecutive patients aged 70 to 88 years, referred in one hospital unit of south eastern France, for a comprehensive geriatric assessment (CGA) before cancer treatment initiation.
MEASUREMENTS AND RESULTS
CGA, measures of muscle strength and physical performances were performed at baseline (T0) and at the end of cancer treatment (T1). Appendicular skeletal muscle mass was measured by Dual-energy X-ray absorptiometry (DXA) at the end of treatment. At T0, 8 patients (among 31) had a probable sarcopenia according to European consensus, and 18 had altered physical performance. At T1, 15 patients (among 19) had abnormal one leg balance test. Finally, only one patient had a sarcopenia confirmed by DXA.
CONCLUSION
This preliminary study showed a high prevalence of muscle disorders before initiation of ADT in a population of elderly cancer prostate patients with intermediate frailty status, and an increased risk of falls at the end of ADT. This highlighted the importance of screening for sarcopenia before treatment initiation, to prevent the occurrence or aggravation of sarcopenia by possible adjustment of treatment, and implementation of appropriate exercise and nutrition interventions.
Identifiants
pubmed: 32003412
doi: 10.1007/s12603-019-1294-7
doi:
Substances chimiques
Androgen Antagonists
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
205-209Déclaration de conflit d'intérêts
E. Lechevallier has received honoria from Ipsen, Astellas, Janssen and Boucharat-Recordati. S. Schneider has received grants from Nutricia and honoria from Fresenius Kabi, Nestlé, Grand-Fontaine and Citrage. The other authors declare «none» for potential conflict of interest: AL Couderc, X. Muracciole, E. Nouguerede, D. Rey, P. Champsaur, L. Lalys and P. Villani
Références
BMC Cancer. 2018 Apr 3;18(1):368
pubmed: 29614993
J Am Geriatr Soc. 2006 Jun;54(6):991-1001
pubmed: 16776798
J Am Geriatr Soc. 2017 Jul;65(7):1414-1419
pubmed: 28263373
Urology. 2016 Sep;95:145-50
pubmed: 27318262
Clinics (Sao Paulo). 2019 Apr 08;74:e477
pubmed: 30994709
Int J Urol. 2018 Jan;25(1):45-53
pubmed: 29052905
J Am Geriatr Soc. 1997 Jun;45(6):735-8
pubmed: 9180669
J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M146-56
pubmed: 11253156
Patient Relat Outcome Meas. 2014 Jul 05;5:63-70
pubmed: 25045284
Gerontology. 2015;61(6):491-6
pubmed: 25871733
Cancer. 2013 May 15;119(10):1808-15
pubmed: 23400678
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Age Ageing. 2014 Nov;43(6):748-59
pubmed: 25241753
JAMA. 1963 Sep 21;185:914-9
pubmed: 14044222
J Am Geriatr Soc. 1991 Feb;39(2):142-8
pubmed: 1991946
PLoS One. 2014 Dec 11;9(12):e115060
pubmed: 25503576
Clin Geriatr Med. 2002 Nov;18(4):737-57
pubmed: 12608501
Prog Urol. 2013 Nov;23 Suppl 2:S57-65
pubmed: 24485294
J Am Med Dir Assoc. 2014 Feb;15(2):95-101
pubmed: 24461239
J Am Med Dir Assoc. 2011 May;12(4):249-56
pubmed: 21527165
Gerontologist. 1969 Autumn;9(3):179-86
pubmed: 5349366
Age Ageing. 1988 Jul;17(4):227-35
pubmed: 3177082
Age Ageing. 2019 Jan 1;48(1):16-31
pubmed: 30312372
J Clin Oncol. 2010 Dec 1;28(34):5038-45
pubmed: 21041715
J Clin Oncol. 2012 Sep 10;30(26):3271-6
pubmed: 22649143
Geriatr Gerontol Int. 2018 May;18 Suppl 1:13-22
pubmed: 29745460